Last reviewed · How we verify
NCT04900142
Micropulsed Laser Trabeculoplasty Using Different Parameters
NA trial testing Micropulsed laser trabeculoplasty in Glaucoma, Open-Angle in 50 participants. Status unknown.
20 March 2022
Quick facts
| Lead sponsor | University of Modena and Reggio Emilia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 20 March 2020 |
| Primary completion | 20 March 2022 |
| Estimated completion | 20 June 2022 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- Micropulsed laser trabeculoplasty
Conditions studied
- Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →
Sponsor
University of Modena and Reggio Emilia
Who can join
Eligibility, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, double blinded, clinical trial compares two different parameters setting of micropulsed laser trabeculoplasty for open angle glaucoma. Group one is treated with 1500 mW of Power, Group two with 1000 mW. The other settings (300 micron of diameter, 300 ms of duration, 15% duty cycle) are the same for both groups, and the laser is applied for 360°. The main outcome is to evaluate the IOP (IntraOcular Pressure) lowering effects of both treatments and the safety on the corneal endothelium.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04900142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
- NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
- NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
- NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
- NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
- NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting
Other University of Modena and Reggio Emilia trials
Trials by the same sponsor.
- NCT05282238 — Quantification of Inspiratory Effort Through Nasal Pressure in Patients Undergoing Weaning From Invasive Mechanical Vent · not yet recruiting
- NCT07404423 — OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis · not yet recruiting
- NCT06989385 — CORALINE - Correlation Between Physiological and Clinical Variables and Failure of Non-Invasive Respiratory Support in P · recruiting
- NCT06734949 — CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD · enrolling by invitation
- NCT05043753 — "Fetal gRowth AbnorMality dEtection Trial" · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04900142 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Modena and Reggio Emilia
- Last refreshed: 25 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04900142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing